Rolf Einar Engstad
Direktor/Vorstandsmitglied bei Biotec BetaGlucans AS
Profil
Rolf Einar Engstad is currently the Director at Biotec BetaGlucans AS.
Previously, he worked as the Chief Scientific Officer at ArcticZymes Technologies ASA. He received his graduate and doctorate degrees from the University of Tromso.
Aktive Positionen von Rolf Einar Engstad
Unternehmen | Position | Beginn |
---|---|---|
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Rolf Einar Engstad
Unternehmen | Position | Ende |
---|---|---|
ARCTICZYMES TECHNOLOGIES ASA | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Rolf Einar Engstad
University of Tromso | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
Private Unternehmen | 1 |
---|---|
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |